off-label use of glp-1 agonists for obesity in 2016 Health Disparity Clusters Off Label Prescriptions Glucagon-Like Peptide 1 Receptor Harnessing GLP-1 Receptor Agonists for
Description
This could lead to higher drug prices for patients and healthcare systems

Comparative analysis of cancer risk among glucose-lowering agents Current clinical evidence indicates that various classes of antidiabetic drugs show substantial variability in their association with cancer risk

doi: 10.1111/dom.14280 [DOI] [PMC free article] [PubMed] [Google Scholar] 183.Ushakumari DS, Sladen RN

2015;107(12):djv275

Do you want maximum effectiveness or best value

doi: 10.1210/en.2018-00004 33 SelvarajahVRobertsonDHansenLJermutusLSmithKCoggiAet al
